We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Developed Immunoassay Predicts Benefits of Anti-PD-1 Therapy in NSCLC

By LabMedica International staff writers
Posted on 12 May 2021
Print article
Image: The HISCL-5000 is a fully automated immunoassay system designed for fast, highly sensitive and reliable immunoassay testing (Photo courtesy of Sysmex)
Image: The HISCL-5000 is a fully automated immunoassay system designed for fast, highly sensitive and reliable immunoassay testing (Photo courtesy of Sysmex)
Lung cancer is the most common cause of cancer-related deaths worldwide. However, current targeted therapies and immunotherapies have gradually improved patient survival. Anti-programmed cell death-1 (PD-1) antibodies (Abs) are key drugs in non-small-cell lung cancer treatment; however, clinical benefits with anti-PD-1 monotherapy are limited.

Notably, anti-programmed cell death-1 (PD-1) and anti-PD-ligand1 (PD-L1) antibodies (Abs) as immune-checkpoint inhibitors prolong overall survival in non-small-cell lung cancer (NSCLC), which accounts for approximately 80% of lung cancer. However, clinical benefits with anti-PD-1/PD-L1 monotherapy are limited with only 20%–30% overall response rate.

Oncologists at the Kawasaki Medical School, Okayama, Japan and their colleagues obtained sera from advanced NSCLC patients, who received anti-PD-1 monotherapy as standard therapy in a first-line or later setting. Sera were collected within two months before anti-PD-1 monotherapy and were serially done after anti-PD-1 therapy, then frozen and stored at −80 °C until use. ESO-1 and XAGE1 antigen in tumor tissues were immunohistochemically stained in a previous study.

The team developed a fully automated detection system for NY-ESO-1/XAGE1 Abs using an HISCL series (Sysmex, Kobe, Japan), which performs a chemiluminescent sandwich immunoassay. Sera were diluted 400 times with appropriate solution and reacted with magnetic beads coated with recombinant NY-ESO-1 protein or synthetic XAGE1 peptide (GL Biochemistry, Shanghai, China). The investigators also determined serum Abs stability, performed analysis of interfering substances and antigen absorption tests.

The scientists reported that the HISCL system detected specific serum NY-ESO-1/XAGE1 Abs, where levels in ELISA and HISCL were highly correlated. The Ab levels in HISCL were stable at four temperatures, five freeze/thaw cycles, and long-term storage; the levels were not interfered by common blood components. The Abs levels in 15 NSCLC responders to anti-PD-1 monotherapy were significantly higher than those in non-responders and healthy donors. The AUROC was the highest (0.91) in combinatory prediction with NY-ESO-1/XAGE1 Abs.

The authors concluded that they had developed a fully automated immunoassay system, HISCL, measuring serum NY-ESO-1/XAGE1 Abs that can predict clinical benefits with anti-PD-1 monotherapy in NSCLC. Their serum biomarkers measured using HISCL are clinically meaningful, as the serum Abs obtained noninvasively were relatively stable at various conditions and could be measured easily and rapidly. The study was published on April, 15, 2021 in the journal Clinica Chimica Acta.

Related Links:
Kawasaki Medical School
Sysmex
GL Biochemistry


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.